Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-38231
Titel: | Thrombus Aspiration in ThrOmbus containing culpRiT lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI): study protocol for a randomized controlled trial |
VerfasserIn: | de Waha, Suzanne Eitel, Ingo Desch, Steffen Scheller, Bruno Böhm, Michael Lauer, Bernward Gawaz, Meinrad Geisler, Tobias Gunkel, Oliver Bruch, Leonhard Klein, Norbert Pfeiffer, Dietrich Schuler, Gerhard Zeymer, Uwe Thiele, Holger |
Sprache: | Englisch |
Titel: | Trials |
Bandnummer: | 14 |
Seiten: | 1-10 |
Verlag/Plattform: | BMC |
Erscheinungsjahr: | 2013 |
Freie Schlagwörter: | : Non-ST-elevation myocardial infarction Thrombectomy Cardiac magnetic resonance imaging Microvascular obstruction |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Current guidelines recommend thrombus aspiration in patients with ST-elevation myocardial infarction (STEMI); however, there are insufficient data to unequivocally support thrombectomy in patients with non-STEMI (NSTEMI). Methods/Design The TATORT-NSTEMI (Thrombus Aspiration in ThrOmbus containing culpRiT lesions in Non-ST-Elevation Myocardial Infarction) trial is a prospective, controlled, multicenter, randomized, open-label trial enrolling 460 patients. The hypothesis is that, against a background of early revascularization, adjunctive thrombectomy leads to less microvascular obstruction (MO) compared with conventional percutaneous coronary intervention (PCI) alone, as assessed by cardiac magnetic resonance imaging (CMR) in patients with NSTEMI. Patients will be randomized in a 1:1 fashion to one of the two treatment arms. The primary endpoint is the extent of late MO assessed by CMR. Secondary endpoints include early MO, infarct size, and myocardial salvage assessed by CMR as well as enzymatic infarct size and angiographic parameters, such as thrombolysis in myocardial infarction flow post-PCI and myocardial blush grade. Furthermore, clinical endpoints including death, myocardial re-infarction, target vessel revascularization, and new congestive heart failure will be recorded at 6 and 12 months. Safety will be assessed by the incidence of bleeding and stroke. Summary The TATORT-NSTEMI trial has been designed to test the hypothesis that thrombectomy will improve myocardial perfusion in patients with NSTEMI and relevant thrombus burden in the culprit vessel reperfused by early PCI. |
DOI der Erstveröffentlichung: | 10.1186/1745-6215-14-110 |
URL der Erstveröffentlichung: | https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-110 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-382315 hdl:20.500.11880/34506 http://dx.doi.org/10.22028/D291-38231 |
ISSN: | 1745-6215 |
Datum des Eintrags: | 25-Nov-2022 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Innere Medizin |
Professur: | M - Prof. Dr. Michael Böhm |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
1745-6215-14-110.pdf | 507,55 kB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons